The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer

Journal of Urology

Volumn 171, Issue 3, 2004, Pages 1137-1140

  Laverdière, Jacques ^a   Nabid, Abdenour ^b   De Bedoya, Luis Diaz ^a   Ébacher, Annie ^a   Fortin, André ^a   Wang, Chang Shu ^a   Harel, François ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Androgens; Prostate; Prostate specific antigen; Prostatic neoplasms; Radiotherapy

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE;

EID: 1542267900     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000112979.97941.7f     Document Type: Article

References (17)

1. Kupelian, P. A., Elshaikh, M., Reddy, C. A., Zippe, C. and Klein, E. A.: Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol, 20: 3376, 2002
2. Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G. et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med, 337: 295, 1997
3. Pilepich, M. V., Caplan, R., Byhardt, R. W., Lawton, C. A., Gallagher, M. J., Mesic, J. B. et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol, 15: 1013, 1997
4. Labrie, F., Cusan, L., Gomez, J. L., Diamond, P., Suburu, E. R., Lemay, M. et al: Down-staging of early stage prostate cancer: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology, 44: 29, 1995
5. Pilepich, M. V., Krall, J., Al-Sarraf, M., Roach, M., III, Doggett, R. L. S., Sause, W. et al: A phase III trial of androgen suppression before and during radiation therapy (RT) for locally advanced prostatic: preliminary report of RTOG protocol 8610. Proc Am Soc Clin Oncol, 12: 229, 1993
6. Vailancourt, L., Ttu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L. et al: Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am J Surg Pathol, 20: 86, 1996
7. Lawton, C. A., Winter, K., Murray, K., Machtay, M., Mesic, J. B., Hanks, G. E. et al: Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys, 49: 937, 2001
8. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R. O. et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Urol Oncol, 21: 309, 2003
9. Roach, M., 3rd, DeSilvio, M., Lawton, C., Uhl, V., Machtay, M., Seider, M. J. et al: Phase III trial comparing whole-pelvis to prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol, 21: 1904, 2003
10. Kaminski, J. M., Hanlon, A. L., Joon, D. L., Meistrich, M., Hachem, P. and Pollack, A.: Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys, 57: 24, 2003
11. Pickles, T., Duncan, G. G., Kim-sing, C., McKenzie, M. R. and Morris, W. J.: PSA relapse definitions - the Vancouver Rules show superior predictive power. Int J Radiat Oncol Biol Phys, 43: 699, 1999
12. Zelefsky, M. J., Leibel, S. A., Gaudin, P. B., Kutcher, G. J., Fleshner, N. E., Venkatramen, E. S. et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys, 41: 491, 1998
13. Grandfors, T., Damber, J. E., Berg, A., Landstrom, M., Lofroth, P. O. and Widmark, A.: Combined castration and fractionated radiotherapy in an experimental prostatic adenocarcinoma. Int J Radiat Oncol Biol Phys, 39: 1031, 1997
14. Gleave, M. E., Goldenberg, S. L., Chin, J. L., Warner, J., Saad, F., Klotz, L. H. et al: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol, 166: 500, 2001
15. Zietman, A. L., Prince, E. A., Nakfoor, B. M. and Park, J. J.: Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys, 38: 1067, 1997
16. Granfors, T., Modig, H., Damber, J.-E. and Tomic, R.: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement. J Urol, 159: 2030, 1998
17. Culig, Z., Klocker, H., Bartsch, G. and Hobish, A.: Androgen receptors in prostate cancer. Endocr Relat Cancer, 9: 155, 2002